Sneezing and coughing are common hay fever symptoms
Hay fever, also known as allergic rhinitis, is a common allergic reaction triggered by pollen binding to molecules called IgE antibodies in the nose, mouth, and eyes. This interaction leads to inflammation and a range of symptoms such as sneezing and itchiness. While treatments like antihistamines and steroids are commonly used to alleviate these symptoms, they often come with side effects like drowsiness and may not be effective for everyone.
A recent study conducted by Kaissar Tabynov and his team at the Kazakh National Agrarian Research University in Kazakhstan has introduced a groundbreaking approach to treat hay fever. They developed a unique “molecular shield” in the form of an antibody that blocks pollen from binding to IgE antibodies, thus preventing the allergic reaction from occurring.
The researchers collected blood samples from mice and isolated an antibody that specifically targets the main allergen in mugwort pollen, a significant trigger for hay fever. This antibody acted as a shield, effectively blocking the allergen from attaching to IgE antibodies in the lab setting.
In a subsequent experiment, the team induced mugwort pollen allergies in mice and administered the pollen-blocking antibody intranasally. The results were promising, with the mice that received the antibody experiencing significantly reduced nasal irritation compared to the control group.
Further analysis of nose tissue samples confirmed that the antibody not only reduced inflammation locally but also had systemic effects within the body. This novel approach demonstrates the potential of using allergen-specific monoclonal antibodies for intranasal therapy in managing plant pollen allergies.
While the study did not assess potential side effects, the researchers believe that this approach is unlikely to cause the adverse reactions associated with traditional hay fever medications, as it targets the allergen at the site of entry.
According to Sayantani Sindher from Stanford University, this study represents a significant advancement in the treatment of allergic rhinitis and sets the stage for future clinical trials in humans. The research team envisions the development of customized antibody sprays for individuals allergic to different types of pollens, offering a tailored and effective treatment option for hay fever sufferers.
Although further adaptation and testing are needed to ensure the efficacy and safety of this approach in humans, the researchers plan to conduct clinical trials using the antibody nasal spray within the next two to three years. This innovative therapy holds promise for improving the quality of life for individuals with hay fever and may pave the way for personalized allergy treatments in the future.
